Savara (SVRA) Cash from Financing Activities (2010 - 2026)
Savara (SVRA) reported Cash from Financing Activities of -$195000.0 for Q1 2026, down 108.41% year-over-year from $2.3 million in Q1 2025, and down 100.14% quarter-over-quarter from $135.6 million in Q4 2025.
Savara (SVRA) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Savara (SVRA) has 17 years of Cash from Financing Activities data on file, last reported at -$195000.0 in Q1 2026.
- Cash from Financing Activities for Q1 2026 came in at -$195000.0, down 108.41% year-over-year; the trailing twelve-month figure through Mar 2026 was $135.3 million (up 12.89% YoY), and the FY2025 annual result was $137.8 million, up 17.2% from the prior year.
- Cash from Financing Activities declined to -$195000.0 in Q1 2026 per SVRA's latest filing, from $135.6 million in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $135.6 million in Q4 2025 and troughed at -$843000.0 in Q4 2024.
- A 5-year average of $19.9 million and a median of $49000.0 in 2024 frame the typical range for Cash from Financing Activities.
- The sharpest annual moves came in 2023 and 2025: Cash from Financing Activities jumped 7475600.0% in 2023, then plunged 189.09% in 2025.
- A 5-year view of Cash from Financing Activities shows it stood at $1000.0 in 2022, then surged by 789400.0% to $7.9 million in 2023, then plunged by 110.68% to -$843000.0 in 2024, then jumped by 16180.66% to $135.6 million in 2025, then plunged by 100.14% to -$195000.0 in 2026.
- Business Quant data shows SVRA's Cash from Financing Activities at -$195000.0 in Q1 2026, $135.6 million in Q4 2025, and -$23000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 7.00 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -600,000.00 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 53,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -538.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 85,464.43 |
| 10 | Savara | 1.39 Bn | 1.39 Bn | - | -195,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -195,000.00 |
| Mar 31, 2026 | -195,000.00 |
| Dec 31, 2025 | 135.56 Mn |
| Dec 31, 2025 | 135.56 Mn |
| Sep 30, 2025 | -23,000.00 |
| Sep 30, 2025 | -23,000.00 |
| Jun 30, 2025 | -49,000.00 |
| Jun 30, 2025 | -49,000.00 |
| Mar 31, 2025 | 2.32 Mn |
| Mar 31, 2025 | 2.32 Mn |
| Dec 31, 2024 | -843,000.00 |
| Dec 31, 2024 | -843,000.00 |
| Sep 30, 2024 | 118.32 Mn |
| Sep 30, 2024 | 118.32 Mn |
| Jun 30, 2024 | 55,000.00 |
| Jun 30, 2024 | 55,000.00 |
| Mar 31, 2024 | 49,000.00 |
| Mar 31, 2024 | 49,000.00 |
| Dec 31, 2023 | 7.90 Mn |
| Dec 31, 2023 | 7.90 Mn |